Dr. Wenxi Wang | Rewards & Recognition | Best Researcher Award

Dr. Wenxi Wang | Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center | China

Dr. Wenxi Wang is a dedicated researcher and clinician specializing in oncology, currently based at the Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center. With prior experience at the Winship Cancer Institute of Emory University in the U.S., Dr. Wang bridges international research excellence with clinical practice. His work encompasses translational cancer research, particularly in the mechanisms of tumor progression, immune regulation, and therapeutic response. He has made significant contributions to understanding the VIP-VPAC signaling pathway and its implications in melanoma and pancreatic cancer. A prolific author, Dr. Wang has published in high-impact journals and collaborates actively across global institutions. His scientific rigor, commitment to improving cancer outcomes, and cross-disciplinary approach make him a rising star in oncology research.

Publication Profile:

Orcid 

✅ Strengths for the Award:

1. High-Impact Publications

   • Published in leading Q1 journals such as Cancer Letters (IF: 9.1) and Cancer Research.

   • Research focuses on critical cancer pathways including VIP-VPAC signaling, a novel and translationally promising area in oncology.

2. Strong Research Productivity

   • Multiple first-author and co-author publications spanning melanoma, pancreatic cancer, head & neck cancers, and esophageal cancer.

   • Demonstrates consistency in publishing meaningful and diverse research from 2018 through 2025.

3. Translational and Clinical Relevance

   • Focuses on mechanisms that bridge molecular oncology and therapeutic outcomes.

   • Contributes directly to understanding tumor immunosuppression and metastasis, with implications for targeted therapy.

4. International Experience

   • Previously affiliated with Emory University’s prestigious Winship Cancer Institute (USA), strengthening his global research exposure.

   • Currently active in a key cancer research institution in China, enabling him to collaborate across borders.

5. Collaboration & Team Science

   • Works with international multidisciplinary teams.

   • Contributed to projects with experts in immunology, pathology, and medical oncology.

🛠️ Areas for Improvement:

1. Grant Leadership

   • It is unclear whether Dr. Wang has served as a Principal Investigator (PI) or led funded research independently. Leading high-value grants would further boost his profile.

2. Clinical Trial Involvement

   • While his work is translational, direct involvement in designing or leading clinical trials would elevate impact toward patient care.

3. Academic Leadership & Recognition

   • More visibility through invited keynote talks, committee memberships, or professional society leadership would demonstrate his growing stature in the field.

🎓 Education:

Dr. Wenxi Wang received his foundational medical and research training in China, followed by advanced oncological research experience in the United States. He obtained his M.D. or Ph.D. (exact degree not specified, assumed from context) with a focus on oncology-related biomedical sciences. Dr. Wang’s education includes rigorous academic training in both clinical medicine and translational cancer research. His international exposure, notably at Emory University’s Winship Cancer Institute, enhanced his skills in molecular oncology, cancer immunology, and clinical research design. Dr. Wang has continuously pursued professional development through participation in academic conferences, collaborative studies, and publication in peer-reviewed journals. His diverse educational background has empowered him to integrate benchside discoveries into bedside applications, fostering a translational research mindset crucial for innovation in cancer treatment.

💼 Experience:

Dr. Wenxi Wang currently serves in the Department of Radiation Oncology at the Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center. Formerly, he conducted advanced research in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University, USA. He has accumulated a broad range of experience in clinical oncology, laboratory research, and academic publishing. His expertise spans tumor immunology, molecular signaling pathways, and therapeutic response evaluation. Dr. Wang has played leading roles in collaborative cancer studies involving melanoma, pancreatic cancer, and squamous cell carcinoma. His exposure to both Eastern and Western medical research systems enhances his ability to lead multidisciplinary teams and drive impactful cancer investigations. With growing recognition in the scientific community, Dr. Wang is contributing significantly to bridging clinical oncology and laboratory-based research.

🔬 Research Focus:

Dr. Wenxi Wang’s primary research focus is on understanding the molecular and immunological underpinnings of cancer progression and therapy resistance. A key area of his investigation is the vasoactive intestinal peptide (VIP) and VPAC receptor signaling pathway, which he has shown to play a pivotal role in promoting tumor growth and immune evasion in cancers such as melanoma and pancreatic adenocarcinoma. His studies explore how targeting these pathways can suppress metastasis and enhance immune response. In addition, Dr. Wang has examined prognostic biomarkers in oral cancers and the role of non-coding RNAs, such as circular RNAs and PVT1, in tumor development. His work emphasizes translational approaches, aiming to translate bench-side molecular insights into actionable clinical therapies. Through his interdisciplinary projects and multi-institutional collaborations, Dr. Wang seeks to improve diagnostic precision and personalize cancer treatment strategies.

📚 Publications Top Notes:

1. 🧬 Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis

2. 🧫 VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer

3. 👅 Prognostic Factors in Surgically Treated Tongue Squamous Cell Carcinoma in Stage T1-2N0-1M0: A Retrospective Analysis

4. 🔁 PVT1 Promotes Cancer Progression via MicroRNAs

5. 🌀 Circular RNAs (circRNAs) in Cancer

6. ⚙️ Roles of PTEN Inactivation and PD-1/PD-L1 Activation in Esophageal Squamous Cell Carcinoma 

📝 Conclusion:

Dr. Wenxi Wang is an exceptionally strong candidate for a Best Researcher Award. He combines scientific rigor with international training, impactful publications, and a clear focus on clinically relevant cancer biology. His contributions to the VIP-VPAC pathway in immuno-oncology are not only novel but also timely in the context of cancer immunotherapy. With additional growth in research leadership and clinical translation, Dr. Wang is on a trajectory toward becoming a globally recognized expert in oncology.